Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis

We assessed safety and tolerability of treatment with pirfenidone (1602–2403 mg·day(−1)) and nintedanib (200–300 mg·day(−1)) in patients with idiopathic pulmonary fibrosis (IPF). This 24-week, single-arm, open-label, phase IV study (ClinicalTrials.gov identifier NCT02598193) enrolled patients with I...

Descripción completa

Detalles Bibliográficos
Autores principales: Flaherty, Kevin R., Fell, Charlene D., Huggins, J. Terrill, Nunes, Hilario, Sussman, Robert, Valenzuela, Claudia, Petzinger, Ute, Stauffer, John L., Gilberg, Frank, Bengus, Monica, Wijsenbeek, Marlies
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092682/
https://www.ncbi.nlm.nih.gov/pubmed/29946005
http://dx.doi.org/10.1183/13993003.00230-2018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092682/
https://www.ncbi.nlm.nih.gov/pubmed/29946005
http://dx.doi.org/10.1183/13993003.00230-2018

Ejemplares similares